Shanghai Henlius Biotech (Henlius) released its seventh ESG report, detailing 2025 performance across product, environmental, social and governance pillars. Key disclosures are as follows:
Product & R&D • Ten biologics are now approved in 60 countries and regions; cumulative patients served exceeded 1.00 million. • Flagship trastuzumab HLX02 is marketed in 50-plus jurisdictions and reimbursed in China, the UK, France and Germany. • Serplulimab secured additional approvals in the EU, UK, India, Singapore and Peru, lifting its footprint to 40-plus markets. • Annual R&D investment reached CNY 2.49 billion, backing a pipeline of more than 50 early-stage assets, including first-/best-in-class ADC HLX43. • All commercial sites passed nearly 100 external GMP inspections; 100 % product testing is performed in-house.
Access & Affordability • Six marketed products are listed in China’s National Reimbursement Drug List; over 100 regional Huiminbao commercial-insurance programmes now include Henlius drugs. • Long-term donation or patient-assistance schemes for serplulimab have been rolled out in India, Indonesia, the Netherlands and Hong Kong.
Talent & Safety • Total headcount rose to 3,762, of which 53 % are female; average training hours reached 70.58 per employee with 98.54 % coverage. • Both Shanghai production sites hold ISO 45001:2018 certification; zero work-related fatalities were reported in 2025.
Environment • All manufacturing facilities achieved ISO 14001:2015 certification. • Henlius cut NOx emissions by 11.6 % and general industrial solid-waste discharges by 13.6 % year-on-year. • Comprehensive energy consumption totalled 219,625 GJ; Scope 1+2 GHG emissions were 21,519.51 tCO₂-e. • New 2030 targets: reduce Scope 1+2 carbon-emission intensity (per unit revenue) by 25 %, energy-consumption intensity by 25 %, water-use intensity by 20 % and hazardous-waste intensity by 10 % versus the 2025 baseline.
Governance & Compliance • The board comprises 11 directors (four independent) with an ESG Committee overseeing sustainability strategy; two ESG-focused board meetings were held in 2025. • Henlius conducted 86 compliance trainings (4,886 attendances) and completed annual compliance certification for 100 % of employees. • No corruption, unfair-competition or data-privacy violations were recorded during the year.
Supply Chain • Henlius manages 985 suppliers; 86 % of local suppliers are integrated into its GMP system and on-time-in-full delivery reached 99.9 %. • Green Supply Chain Clauses are now mandatory for direct-procurement partners; localisation projects cover affinity resins, single-use systems and chemically defined media.
Community Investment • Public-welfare donations totalled CNY 91.80 million, including continued “Rural Healthcare Charity Initiative” outreach to 40 remote counties since inception.
Looking ahead, the company targets deeper global market penetration, expanded smart-manufacturing capabilities and fulfilment of newly announced 2026-2030 environmental intensity goals.
Comments